- Home
- MLYS vs GRAL Comparison
MLYS vs GRAL Comparison
Compare MLYS & GRAL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MLYS
- GRAL
- Stock Information
- Founded
- MLYS 2019
- GRAL 2016
- Country
- MLYS United States
- GRAL United States
- Employees
- MLYS N/A
- GRAL N/A
- Industry
- MLYS Biotechnology: Pharmaceutical Preparations
- GRAL
- Sector
- MLYS Health Care
- GRAL
- Exchange
- MLYS Nasdaq
- GRAL NYSE
- Market Cap
- MLYS 634.6M
- GRAL 610.9M
- IPO Year
- MLYS 2023
- GRAL N/A
- Fundamental
- Price
- MLYS $9.50
- GRAL $17.41
- Analyst Decision
- MLYS Strong Buy
- GRAL Hold
- Analyst Count
- MLYS 2
- GRAL 2
- Target Price
- MLYS $30.00
- GRAL $16.00
- AVG Volume (30 Days)
- MLYS 251.9K
- GRAL 986.6K
- Earning Date
- MLYS 11-11-2024
- GRAL 02-15-2025
- Dividend Yield
- MLYS N/A
- GRAL N/A
- EPS Growth
- MLYS N/A
- GRAL N/A
- EPS
- MLYS N/A
- GRAL N/A
- Revenue
- MLYS N/A
- GRAL $117,669,000.00
- Revenue This Year
- MLYS N/A
- GRAL $32.48
- Revenue Next Year
- MLYS N/A
- GRAL $14.72
- P/E Ratio
- MLYS N/A
- GRAL N/A
- Revenue Growth
- MLYS N/A
- GRAL 111.83
- 52 Week Low
- MLYS $7.95
- GRAL $12.33
- 52 Week High
- MLYS $16.91
- GRAL $24.92
- Technical
- Relative Strength Index (RSI)
- MLYS 33.43
- GRAL N/A
- Support Level
- MLYS $8.60
- GRAL N/A
- Resistance Level
- MLYS $9.97
- GRAL N/A
- Average True Range (ATR)
- MLYS 0.89
- GRAL 0.00
- MACD
- MLYS -0.33
- GRAL 0.00
- Stochastic Oscillator
- MLYS 18.63
- GRAL 0.00
About MLYS Mineralys Therapeutics Inc.
Mineralys Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing medicines to target diseases driven by abnormally elevated aldosterone. The company's product candidate, lorundrostat, is a proprietary, orally administered, selective aldosterone synthase inhibitor, that is initially developed for the treatment of patients with uncontrolled hypertension, defined as individuals who are unable to achieve BP of below 130/80 mmHg despite taking two or more lines of antihypertensive medication or resistant hypertension, defined as individuals who are unable to achieve BP of below 130/80 mmHg despite taking three or more antihypertensive medications typically including a diuretic.
About GRAL GRAIL INC
GRAIL Inc is a healthcare company focused on developing technologies for early cancer detection. The company has developed a multi-cancer early detection blood test that has the ability to detect all types of cancer, across all stages.